Companies
CapsoVision
its CapsoCam Plus capsule endoscopy device has cleared approval for pediatric use, with the company reporting its first-quarter 2026 financial results as a public company.
- Country
- United States
Commercial
CapsoCam Plus capsule endoscopy
Coverage
| CN | EU | US | |
|---|---|---|---|
| diagnostics-medtech | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $14 million private placement closed on March 16, 2026 | globenewswire.com · sec.gov |
| Revenue | $3.6 million for second quarter 2026; $2.8 million for first quarter 2026 | investors.capsovision.com · biospace.com · globenewswire.com · sec.gov |
| Regulatory approval | FDA clearance for pediatric use (age two and above) announced January 9, 2025 | capsovision.com · investors.capsovision.com |
| Certification | ISO 27001 certification achieved December 4, 2020 | capsovision.com |
| Production site | Components sourced primarily from Asia, particularly Taiwan and Japan medium confidence | sec.gov |
Independent sources: biospace.com · globenewswire.com · sec.gov
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Ingestible biosensors / smart pills | diagnostics-medtech | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.